|Table of Contents|

Research progress of protein arginine methyltransferase 5 in acute myeloid leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 05
Page:
892-895
Research Field:
Publishing date:

Info

Title:
Research progress of protein arginine methyltransferase 5 in acute myeloid leukemia
Author(s):
ZHAO Lu1; 2; WANG Jishi1
1.Department of Hematology,the Affiliated Hospital of Guizhou Medical University,Guizhou Guiyang 550004,China;2.Department of Hematology,Second Affiliated Hospital,Army Medical University,Chongqing 400037,China.
Keywords:
protein arginine methyltransferase 5; acute myeloid leukemia; protein arginine methylation
PACS:
R733.71
DOI:
10.3969/j.issn.1672-4992.2021.05.039
Abstract:
Acute myeloid leukemia (AML) is a common malignant hematological tumor.Epigenetic modification can play a key role in the progress of AML through post-transcriptional methylation.Protein arginine methyltransferase 5 (PRMT5) is a type Ⅱ protein arginine methyltransferase.Through catalysis,the methyl of S-adenosylmethionine could be transferred to the guanidine nitrogen atom of arginine to form methyl arginine and S-adenosylhomocysteine.In recent years,it has been found that PRMT5 could promote the occurrence and development of AML by regulating post-transcriptional methylation and mRNA splicing of tumor-related genes.This paper reviewed the research progress of PRMT5 in AML and summarized the therapeutic effect of PRMT5 inhibitors on AML.

References:

［1］SHORT NJ,RYTTING ME,CORTES JE.Acute myeloid leukaemia［J］.Lancet,2018,392(10147):593-606.
［2］Cancer Genome Atlas Research N,LEY TJ,MILLER C,et al.Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia［J］.N Engl J Med,2013,368(22):2059-2074.
［3］SHLUSH LI,MITCHELL A,HEISLER L,et al.Tracing the origins of relapse in acute myeloid leukaemia to stem cells［J］.Nature,2017,547(7661):104-108.
［4］STROBL CD,SCHAFFER S,HAUG T,et al.Selective PRMT5 inhibitors suppress human CD8(+) T cells by upregulation of p53 and impairment of the AKT pathway similar to the tumor metabolite MTA［J］.Mol Cancer Ther,2020,19(2):409-419.
［5］SECKER KA,KEPPELER H,DUERR-STOERZER S,et al.Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9［J］.Oncogene,2019,38(46):7181-7195.
［6］HERNANDEZ-VALLADARES M,WANGEN R,BERVEN FS,et al.Protein post-translational modification crosstalk in acute myeloid leukemia calls for action［J］.Curr Med Chem,2019,26(28):5317-5337.
［7］BLANC RS,RICHARD S.Arginine methylation:The coming of age［J］.Mol Cell,2017,65(1):8-24.
［8］RICHTERS A.Targeting protein arginine methyltransferase 5 in disease［J］.Future Med Chem,2017,9(17):2081-2098.
［9］YANG Y,HADJIKYRIACOU A,XIA Z,et al.PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145［J］.Nat Commun,2015,6:6428.
［10］YANG Y,BEDFORD MT.Protein arginine methyltransferases and cancer［J］.Nat Rev Cancer,2013,13(1):37-50.
［11］XIAO W,CHEN X,LIU L,et al.Role of protein arginine methyltransferase 5 in human cancers［J］.Biomed Pharmacother,2019,114:108790.
［12］FENG Y,MAITY R,WHITELEGGE JP,et al.Mammalian protein arginine methyltransferase 7 (PRMT7) specifically targets RXR sites in lysine- and arginine-rich regions［J］.J Biol Chem,2013,288(52):37010-37025.
［13］ZHU F,RUI L.PRMT5 in gene regulation and hematologic malignancies［J］.Genes Dis,2019,6(3):247-257.
［14］AUCLAIR Y,RICHARD S.The role of arginine methylation in the DNA damage response［J］.DNA Repair (Amst),2013,12(7):459-465.
［15］GAO G,ZHANG L,VILLARREAL OD,et al.PRMT1 loss sensitizes cells to PRMT5 inhibition［J］.Nucleic Acids Res,2019,47(10):5038-5048.
［16］KOH CM,BEZZI M,GUCCIONE E.The where and the how of PRMT5［J］.Current Molecular Biology Reports,2015,1(1):19-28.
［17］HAMARD PJ,SANTIAGO GE,LIU F,et al.PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes［J］.Cell Rep,2018,24(10):2643-2657.
［18］TAN DQ,LI Y,YANG C,et al.PRMT5 modulates splicing for genome integrity and preserves proteostasis of hematopoietic stem cells［J］.Cell Rep,2019,26(9):2316-2328,e6.
［19］LORTON BM,SHECHTER D.Cellular consequences of arginine methylation［J］.Cell Mol Life Sci,2019,76(15):2933-2956.
［20］GE L,WANG H,XU X,et al.PRMT5 promotes epithelial-mesenchymal transition via EGFR-beta-catenin axis in pancreatic cancer cells［J］.J Cell Mol Med,2020,24(2):1969-1979.
［21］BANDYOPADHYAY S,HARRIS DP,ADAMS GN,et al.HOXA9 methylation by PRMT5 is essential for endothelial cell expression of leukocyte adhesion molecules［J］.Mol Cell Biol,2012,32(7):1202-1213.
［22］COLLINS CT,HESS JL.Role of HOXA9 in leukemia:dysregulation,cofactors and essential targets［J］.Oncogene,2016,35(9):1090-1098.
［23］SHAILESH H,ZAKARIA ZZ,BAIOCCHI R,et al.Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer［J］.Oncotarget,2018,9(94):36705-36718.
［24］LIU M,YAO B,GUI T,et al.PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression［J］.Theranostics,2020,10(10):4437-4452.
［25］LITZLER LC,ZAHN A,MELI AP,et al.PRMT5 is essential for B cell development and germinal center dynamics［J］.Nat Commun,2019,10(1):22.
［26］WEBB LM,NARVAEZ MIRANDA J,AMICI SA,et al.NF-kappaB/mTOR/MYC axis drives PRMT5 protein induction after T cell activation via transcriptional and non-transcriptional mechanisms［J］.Front Immunol,2019,10:524.
［27］KIM JH,YOO BC,YANG WS,et al.The role of protein arginine methyltransferases in inflammatory responses［J］.Mediators Inflamm,2016,2016:4028353.
［28］LIU F,CHENG G,HAMARD PJ,et al.Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis［J］.J Clin Invest,2015,125(9):3532-3544.
［29］TARIGHAT SS,SANTHANAM R,FRANKHOUSER D,et al.The dual epigenetic role of PRMT5 in acute myeloid leukemia:gene activation and repression via histone arginine methylation［J］.Leukemia,2016,30(4):789-799.
［30］KAUSHIK S,LIU F,VEAZEY KJ,et al.Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML［J］.Leukemia,2018,32(2):499-509.
［31］BELLUTTI F,TIGAN AS,NEBENFUEHR S,et al.CDK6 antagonizes p53-induced responses during tumorigenesis［J］.Cancer Discov,2018,8(7):884-897.
［32］URAS IZ,WALTER GJ,SCHEICHER R,et al.Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6［J］.Blood,2016,127(23):2890-2902.
［33］黄美玲，肖晶晶，延常姣，等.蛋白质精氨酸加急转移酶5抑制剂的研究进展［J］.现代肿瘤医学,2019,27(08):1432-1435. HUANG ML,XIAO JJ,YAN CJ,et al.Research progress of protein arginine methyltransferase 5 inhibitors［J］.Modern Oncology,2019,27(08):1432-1435.
［34］LIN H,LUENGO JI.Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors［J］.Bioorg Med Chem Lett,2019,29(11):1264-1269.
［35］ HU H,QIAN K,HO MC,et al.Small molecule inhibitors of protein arginine methyltransferases［J］.Expert Opin Investig Drugs,2016,25(3):335-358.
［36］ WANG Q,XU J,LI Y,et al.Identification of a novel protein arginine methyltransferase 5 inhibitor in non-small cell lung cancer by structure-based virtual screening［J］.Front Pharmacol,2018,9:173.
［37］FEDORIW A,RAJAPURKAR SR,O'BRIEN S,et al.Anti-tumor activity of the type I PRMT inhibitor,GSK3368715,synergizes with PRMT5 inhibition through MTAP loss［J］.Cancer Cell,2019,36(1):100-114,e25.
［38］ LI Y,CHITNIS N,NAKAGAWA H,et al.PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers［J］.Cancer Discov,2015,5(3):288-303.
［39］ WEBB LM,AMICI SA,JABLONSKI KA,et al.PRMT5-selective inhibitors suppress inflammatory T cell responses and experimental autoimmune encephalomyelitis［J］.J Immunol,2017,198(4):1439-1451.

Memo

Memo:
National Natural Science Foundation of China（No.81960032）;国家自然科学基金（编号：81960032）
Last Update: 2021-01-29